Table 1.
Clinicopathological characteristics of patient samples and expression of PNN in prostate cancer
| Characteristics | Number of Patients | Percentage (%) |
|---|---|---|
| PSA Level (ng/ml) | ||
| < 10 | 11 | 13.6 |
| 10-50 | 34 | 42.0 |
| > 50 | 36 | 44.4 |
| Gleason Score | ||
| 6 | 13 | 16.0 |
| 7 | 21 | 25.9 |
| 8 | 25 | 30.9 |
| 9 | 18 | 22.2 |
| 10 | 4 | 4.9 |
| Tumor Stage | ||
| I | 2 | 2.5 |
| II | 52 | 64.2 |
| III | 17 | 21.0 |
| IV | 9 | 11.1 |
| Unknown | 1 | 1.2 |
| Tumor Metastasis | ||
| Yes | 45 | 55.6 |
| No | 35 | 43.2 |
| Unknown | 1 | 1.2 |
| Biochemical recurrence | ||
| Yes | 20 | 24.7 |
| No | 61 | 75.3 |
| PNN Expression in Tumors | ||
| Negative | 5 | 6.2 |
| Low | 38 | 46.9 |
| Moderate | 33 | 40.7 |
| High | 5 | 6.2 |
| PNN Expression in Normal samples | ||
| Negative | 15 | 68.2 |
| Low | 7 | 31.8 |